Novavax Inc. (NASDAQ:NVAX)’s share price fell 1.6% during trading on Thursday . The company traded as low as $7.19 and last traded at $7.24, with a volume of 2,778,483 shares. The stock had previously closed at $7.36.

A number of brokerages have commented on NVAX. Chardan Capital reiterated a “neutral” rating on shares of Novavax in a report on Monday, May 2nd. Wedbush reiterated an “outperform” rating and issued a $14.00 target price on shares of Novavax in a report on Wednesday, May 25th. Zacks Investment Research downgraded shares of Novavax from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Finally, Vetr downgraded shares of Novavax from a “strong-buy” rating to a “buy” rating and set a $8.02 target price for the company. in a report on Wednesday, June 29th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $11.05.

The company’s market cap is $1.95 billion. The stock’s 50-day moving average is $7.39 and its 200-day moving average is $5.89.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.04. The company earned $2.50 million during the quarter, compared to analysts’ expectations of $8.03 million. The company’s revenue was down 82.1% on a year-over-year basis. During the same period last year, the firm earned ($0.08) earnings per share. Analysts forecast that Novavax Inc. will post ($1.07) EPS for the current year.

In related news, Director Gary C. Evans sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $5.41, for a total transaction of $270,500.00. Following the completion of the transaction, the director now directly owns 357,111 shares in the company, valued at approximately $1,931,970.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gary C. Evans sold 18,998 shares of the firm’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $6.50, for a total value of $123,487.00. Following the transaction, the director now owns 321,979 shares of the company’s stock, valued at $2,092,863.50. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Novavax stock. Rhumbline Advisers increased its stake in shares of Novavax Inc. (NASDAQ:NVAX) by 12.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 271,881 shares of the biopharmaceutical company’s stock after buying an additional 30,395 shares during the period. Rhumbline Advisers owned 0.10% of Novavax worth $2,281,000 at the end of the most recent quarter.

Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.